Pharmacogenomic (PGx) Analysis of Bortezomib-Associated Peripheral Neuropathy in the Phase 3 VISTA Trial of Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone in Multiple Myeloma.

Deborah S Ricci,Reyna Favis,Yu Sun,Helgi Van De Velde,Erin Broderick,Michael Meyers,Jean-Luc Harousseau,Hervé Avet-Loiseau,Paul G Richardson,Jesús F San Miguel

doi:10.1182/blood.v114.22.3875.3875

Pharmacogenomic (PGx) Analysis of Bortezomib-Associated Peripheral Neuropathy in the Phase 3 VISTA Trial of Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone in Multiple Myeloma.

Deborah S Ricci, Reyna Favis + Show 8 more

https://doi.org/10.1182/blood.v114.22.3875.3875

Copy DOI

Export

Save

Cite

Journal: Blood	Publication Date: Nov 20, 2009
Citations: 5

Affiliation: Johnson & Johnson (United States), Institut Génétique Nantes Atlantique, Centre Hospitalier Universitaire de Nantes, Dana-Farber Cancer Institute, Centro de Investigación del Cáncer

#Peripheral Neuropathy #Onset Of Peripheral Neuropathy #Advisory Committees #Entity's Board #Board Of Directors #Speakers Bureau #Bonferroni's Method #Untreated Multiple Myeloma Patients #Equity Ownership #Untreated Multiple Myeloma

Abstract
Full-Text
Similar Papers

Abstract

Listen

Pharmacogenomic (PGx) Analysis of Bortezomib-Associated Peripheral Neuropathy in the Phase 3 VISTA Trial of Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone in Multiple Myeloma.

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Blood

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

Pharmacogenomic (PGx) Analysis of Bortezomib-Associated Peripheral Neuropathy in the Phase 3 VISTA Trial of Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone in Multiple Myeloma.